Q910.F Annexin Pharmaceuticals AB (publ)

Healthcare Biotechnology Frankfurt Exchange
0.7820 EUR
Close of Nov 12, 2026
0.5580 2.26
Market cap
EUR 6.82M
P/E
-
P/B
32.02x
ROE
-1,750.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is Q910.F undervalued?

Graham number

The Graham number of Annexin Pharmaceuticals AB (publ) cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Annexin Pharmaceuticals AB (publ) fundamental analysis

No fundamental analysis for Annexin Pharmaceuticals AB (publ) yet.

Annexin Pharmaceuticals AB (publ) stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Annexin Pharmaceuticals AB (publ)

Annexin Pharmaceuticals AB (publ), a clinical stage biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases. It develops ANXV, a human recombinant protein and Annexin A5, natural protein that protects and repairs cells, as well as counteract unwanted inflammatory and immune cell reactions that is in phase 2 clinical phase for the treatment of ophthalmology, oncology, sickle cell disease, and cardiovascular disease. Annexin Pharmac…

Full company profile